✦ LIBER ✦

The Economic Burden Of Dasatinib And Nilotinib Treatment Failure In Chronic Myeloid Leukemia (Cml) Patients: A Real-World Analysis

✍ Scribed by Pokras, S.M.; Divino, V.; Ferrufino, C.P.; R.J.G., Arnold; Huang, H.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN13 Cost-Effectiveness Analysis of Nil

✍ Niu, X.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

A retrospective analysis of therapy adhe

✍ Guérin, Annie; Chen, Lei; Wu, Eric Q.; Ponce de Leon, Diego; Griffin, James D. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 174 KB

PCN34 BUDGET IMPACT ANALYSIS OF DASATINI

✍ E Asano; M Nita; A Moellmann-Coelho; R Rached; B Donato; E Rahal 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Cost-Utility Analysis of Dasatinib and N

✍ Kulpeng, Wantanee; Sompitak, Sumalai; Jootar, Saengsuree; Chansung, Kanchana; Te 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 433 KB

PCN11 COST-UTILITY ANALYSIS OF DASATINIB

✍ JFS Logman; MJ Taylor; K Neumann; L Kutikova; KH Cerri; BA Van Hout; T Kühr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

The development of dasatinib as a treatm

✍ Hochhaus, Andreas; Kantarjian, Hagop 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 340 KB